Zimbabwe has rejected a major US healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years due to the United States' insistence on confidential biological samples.
The decision was revealed following a internal memorandum dated December was leaked, which showed Head of State Emmerson Mnangagwa believed the deal was "lopsided".
An official spokesperson has since clarified that the United States was requesting genetic material for scientific study and commercial gain while refused to share the benefits from future treatments.
"We are forced to start the difficult and regrettable process of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided more than $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for more talks to reach a agreement acceptable to both sides so the nation's critical HIV treatment initiative can proceed.
Broader Background
This rejection follows a similar case in Kenya, where a high court halted a similar health funding agreement after legal challenges were raised about the safety of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
USAID had overseen aid for the American government, but Trump claimed its spending was "inefficient" and his administration was pursuing government-to-government deals to boost openness and accountability.
As per reports, 16 African countries have to date agreed to similar agreements, representing more than $18.3bn of fresh investment.
Specifics of the Declined Agreement
The money for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership could have provided immense advantages for Zimbabwean communities, especially the 1.2 million currently receiving HIV treatment through American-funded programmes," Tremont said.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"Our nation was requested to surrender its biological resources and data indefinitely, with no equivalent assurance of access to any medical innovations – like new medicines or tests – that might be developed from that provided information," Mangwana explained.
"In essence, our country would supply the basic resources for scientific discovery with no certainty that the final treatments would be accessible to our population if a new health crisis arise."
Sovereignty and Global Health
He also pointed out that the American exit from the global health body and its push of bilateral deals were undermining frameworks already set up via the international health agency.
Mangwana cited its Pandemic Benefit-Sharing system designed to manage future global health emergencies.
"This framework is intended to ensure that when a country contributes its samples, the benefits – including vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the funds to develop them."
Zimbabwe's reservations over the US deal "are not meant as hostility towards the US," he added.
"We encourage further discussions with our US partners on how future co-operation might be designed in a way that respects the sovereignty and interests of each country."
Health Experts Reaction
Medical experts said it acknowledged the government's concerns, but suggested that talks need to persist considering much of the nation's HIV programmes were funded by foreign aid.
"Where specific concerns exist, including those involving data governance or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," the group commented.
The halted deal highlights the complex debate between accepting much-needed international aid and protecting local interests in an increasingly data-driven world.